Abstract
Major histocompatibility complex (MHC) class I and NK cell receptor gene regions are a paradigm of genomic plasticity as they reveal a considerable degree of diversity, exemplified by high allelic polymorphism, genomic duplications and contractions, and formation of gene families. Both genetic components show signs of rapid evolution due to strong selective pressure to combat pathogens. Comparative analyses of these genomic regions in various primates revealed considerable differences, reflecting species-specific adaptations to pathogenic threat or different strategies to combat infections. MHC and NK receptor genomic diversity in populations are important factors that determine susceptibility or resistance to a variety of diseases including autoimmune and infectious diseases as well as reproductive success.
Keywords: MHC, NK Receptor, Genomic Variability, KIR, NKC, LRC
Current Genomics
Title: Pas de deux: Natural Killer Receptors and MHC Class I Ligands in Primates
Volume: 8 Issue: 1
Author(s): Lutz Walter
Affiliation:
Keywords: MHC, NK Receptor, Genomic Variability, KIR, NKC, LRC
Abstract: Major histocompatibility complex (MHC) class I and NK cell receptor gene regions are a paradigm of genomic plasticity as they reveal a considerable degree of diversity, exemplified by high allelic polymorphism, genomic duplications and contractions, and formation of gene families. Both genetic components show signs of rapid evolution due to strong selective pressure to combat pathogens. Comparative analyses of these genomic regions in various primates revealed considerable differences, reflecting species-specific adaptations to pathogenic threat or different strategies to combat infections. MHC and NK receptor genomic diversity in populations are important factors that determine susceptibility or resistance to a variety of diseases including autoimmune and infectious diseases as well as reproductive success.
Export Options
About this article
Cite this article as:
Walter Lutz, Pas de deux: Natural Killer Receptors and MHC Class I Ligands in Primates, Current Genomics 2007; 8 (1) . https://dx.doi.org/10.2174/138920207780076974
DOI https://dx.doi.org/10.2174/138920207780076974 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
SLN Mediate Active Delivery of Gefitinib into A549 Cell Line: Optimization,
Biosafety and Cytotoxicity Studies
Drug Delivery Letters Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry Genome Wide Analysis of Chlamydia pneumoniae for Candidate Vaccine Development
Current Computer-Aided Drug Design Vaccine Delivery - Current Trends and Future
Current Drug Delivery The Role of Procalcitonin in Sepsis and Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod- induced Psoriatic Mouse Model
Current Vascular Pharmacology Selenium-Rich Foods: a Promising Approach to Colorectal Cancer Prevention
Current Pharmaceutical Biotechnology Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Current Drug Targets Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Early Diagnosis of Multiple Sclerosis Based on Optical and Electrochemical Biosensors: Comprehensive Perspective
Current Analytical Chemistry Interleukin-1β Receptor Antagonism Prevents Cognitive Impairment Following Experimental Bacterial Meningitis
Current Neurovascular Research Gene Therapy for Arthritis
Current Drug Targets Immune Mechanisms and Novel Pharmacological Therapies of Acute Kidney Injury
Current Drug Targets Somatostatin Involvement in Rheumatoid Arthritis
Current Rheumatology Reviews Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Fish and Apoptosis: Studies in Disease and Pharmaceutical Design
Current Pharmaceutical Design Chemical Diversity of Grape Products, a Complex Blend of Bioactive Secondary Metabolites
The Natural Products Journal Nephrotoxicity Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Drug Safety The Offer of Chemistry to Targeted Therapy in Cancer
Recent Patents on Biotechnology Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued)